PMID- 23097067
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20151119
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 15
IP  - 1
DP  - 2013 Jan
TI  - Sildenafil in Heart failure (SilHF). An investigator-initiated multinational 
      randomized controlled clinical trial: rationale and design.
PG  - 119-22
LID - 10.1093/eurjhf/hfs152 [doi]
AB  - AIMS: Heart failure (HF) is a major clinical problem and, despite advances in 
      both pharmacological and device therapy, the mortality remains high and quality 
      of life poor. Over the last decade there has been growing interest in using 
      phosphodiesterase-5 (PDE-5) inhibitors in HF associated with group 2 pulmonary 
      hypertension (PH), with benefits reported on pulmonary haemodynamic and 
      functional status in single-centre trials Methods The Sildenafil in Heart Failure 
      (SilHF) trial is a randomized, placebo-controlled multinational trial designed to 
      assess efficacy and tolerability of PDE-5 inhibition with sildenafil (target dose 
      40 mg three times per day) in 210 patients with HF, New York Heart Association 
      (NYHA) functional class II or III, and evidence of group 2 PH. The co-primary 
      endpoints are patient global assessment and the 6 min walk test. Secondary 
      endpoints include NYHA functional class and the quality of life tools Euro QoL 5D 
      and the Kansas City questionnaire. Patients will be followed up for 6 months. 
      PERSPECTIVE: The authors hypothesize that PDE-5 inhibition can improve exercise 
      capacity and symptoms with acceptable tolerability in patients with HF and group 
      2 PH.
FAU - Cooper, Trond J
AU  - Cooper TJ
AD  - Stavanger University Hospital, Stavanger, Norway. trond.cooper@gmail.com
FAU - Guazzi, Marco
AU  - Guazzi M
FAU - Al-Mohammad, Abdallah
AU  - Al-Mohammad A
FAU - Amir, Offer
AU  - Amir O
FAU - Bengal, Tuvia
AU  - Bengal T
FAU - Cleland, John G
AU  - Cleland JG
FAU - Dickstein, Kenneth
AU  - Dickstein K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20121024
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Dose-Response Relationship, Drug
MH  - Exercise Tolerance/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/*drug therapy/physiopathology/psychology
MH  - Humans
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/administration & dosage
MH  - Piperazines/*administration & dosage
MH  - Purines/administration & dosage
MH  - *Quality of Life
MH  - Sildenafil Citrate
MH  - Stroke Volume/*drug effects
MH  - Sulfones/*administration & dosage
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2012/10/26 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/10/26 06:00
PHST- 2012/10/26 06:00 [entrez]
PHST- 2012/10/26 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - hfs152 [pii]
AID - 10.1093/eurjhf/hfs152 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2013 Jan;15(1):119-22. doi: 10.1093/eurjhf/hfs152. Epub 2012 
      Oct 24.